Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Sell
26
MURA Quote, Financials, Valuation and Earnings
Last price:
$3.22
Seasonality move
:
38.48%
Day range:
$3.19 - $3.37
52-week range:
$2.87 - $6.25
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.32x
Volume:
117.9K
Avg. volume:
224K
1-year change:
-26.86%
Market cap:
$55.3M
Revenue:
--
EPS (TTM):
-$9.14
Analysts' Opinion
-
Consensus RatingMural Oncology PLC has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Mural Oncology PLC has an estimated upside of 404.12% from its current price of $3.24.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $3.24.
Fair Value
-
According to the consensus of 0 analysts, Mural Oncology PLC has 404.12% upside to fair value with a price target of -- per share.
MURA vs. S&P 500
-
Over the past 5 trading days, Mural Oncology PLC has underperformed the S&P 500 by -7.16% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Mural Oncology PLC does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Mural Oncology PLC has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Mural Oncology PLC reported revenues of --.
Earnings Growth
-
Mural Oncology PLC has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Mural Oncology PLC reported earnings per share of -$1.87.
Enterprise value:
-120.2M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.85x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -$185.1M | -$160.9M | -$46.3M | -$34.1M | |
| EBITDA | -- | -$182.6M | -$157.7M | -$45.5M | -$33.2M | |
| Diluted EPS | -- | -$11.77 | -$9.14 | -$3.07 | -$1.87 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | $5M | $183.8M | |
| Total Assets | -- | -- | -- | $30.2M | $203.3M | |
| Current Liabilities | -- | -- | -- | $26.4M | $24.9M | |
| Total Liabilities | -- | -- | -- | $37.1M | $29.1M | |
| Total Equity | -- | -- | -- | -$6.9M | $174.1M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -$139.5M | -$50.5M | -$30.1M | |
| Cash From Investing | -- | -- | -$62.7M | -$1.2M | $19.3M | |
| Cash From Financing | -- | -- | $315.2M | $51.6M | $196K | |
| Free Cash Flow | -- | -- | -$140.7M | -$51.6M | -$30.1M | |
MURA
Sector
Market Cap
$55.3M
$46.1M
Price % of 52-Week High
51.84%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-26.86%
-30.52%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$3.31
200-day SMA
Sell
Level
$3.57
Bollinger Bands (100)
Sell
Level
3.15 - 3.69
Chaikin Money Flow
Sell
Level
-14.8M
20-day SMA
Sell
Level
$3.71
Relative Strength Index (RSI14)
Sell
Level
37.40
ADX Line
Sell
Level
21.23
Williams %R
Neutral
Level
-71.7557
50-day SMA
Sell
Level
$3.59
MACD (12, 26)
Sell
Level
-0.12
25-day Aroon Oscillator
Sell
Level
-68
On Balance Volume
Neutral
Level
10.2M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
--
Momentum Score
Level (--)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
Stock Forecast FAQ
In the current month, MURA has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MURA average analyst price target in the past 3 months is --.
-
Where Will Mural Oncology PLC Stock Be In 1 Year?
According to analysts, the consensus estimate is that Mural Oncology PLC share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Mural Oncology PLC?
Analysts are divided on their view about Mural Oncology PLC share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Mural Oncology PLC is a Sell and believe this share price will drop from its current level to --.
-
What Is Mural Oncology PLC's Price Target?
The price target for Mural Oncology PLC over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MURA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Mural Oncology PLC is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of MURA?
You can purchase shares of Mural Oncology PLC via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Mural Oncology PLC shares.
-
What Is The Mural Oncology PLC Share Price Today?
Mural Oncology PLC was last trading at $3.22 per share. This represents the most recent stock quote for Mural Oncology PLC. Yesterday, Mural Oncology PLC closed at $3.24 per share.
-
How To Buy Mural Oncology PLC Stock Online?
In order to purchase Mural Oncology PLC stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
